Compare TTE & LLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTE | LLY |
|---|---|---|
| Founded | 1924 | 1876 |
| Country | France | United States |
| Employees | 101513 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.5B | 979.6B |
| IPO Year | N/A | 2007 |
| Metric | TTE | LLY |
|---|---|---|
| Price | $80.54 | $1,108.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 19 |
| Target Price | $76.63 | ★ $1,218.84 |
| AVG Volume (30 Days) | 1.4M | ★ 2.4M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.14% | 0.81% |
| EPS Growth | N/A | ★ 95.99 |
| EPS | N/A | ★ 8.26 |
| Revenue | N/A | ★ $65,179,000,000.00 |
| Revenue This Year | $28.83 | $27.15 |
| Revenue Next Year | N/A | $16.04 |
| P/E Ratio | ★ $12.60 | $133.62 |
| Revenue Growth | N/A | ★ 44.70 |
| 52 Week Low | $57.40 | $623.78 |
| 52 Week High | $94.17 | $1,182.73 |
| Indicator | TTE | LLY |
|---|---|---|
| Relative Strength Index (RSI) | 25.14 | 56.02 |
| Support Level | $76.56 | $1,032.70 |
| Resistance Level | $82.21 | $1,108.78 |
| Average True Range (ATR) | 1.44 | 34.34 |
| MACD | -0.88 | -8.59 |
| Stochastic Oscillator | 3.48 | 42.35 |
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2025, it produced 1.5 million barrels of liquids and 5.4 billion cubic feet of natural gas per day. At the end of 2025, reserves stood at 11.2 billion barrels of oil equivalent, 55% of which are liquids. During 2025, it had LNG sales of 43.9 million metric tons. The company owns interests in refineries with a capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. At year-end, its gross installed renewable power generation capacity was 34 gigawatts.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.